What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings?

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Belite Bio in a research note issued on Tuesday, March 3rd. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.71) per share for the quarter, down from their previous forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at $4.05 EPS and FY2026 earnings at $1.89 EPS.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.18.

Other research analysts have also recently issued reports about the stock. BTIG Research set a $187.00 target price on shares of Belite Bio in a research note on Wednesday, December 3rd. Cantor Fitzgerald increased their price objective on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a report on Tuesday. Bank of America started coverage on Belite Bio in a research note on Monday, January 26th. They issued a “buy” rating and a $195.00 target price on the stock. Morgan Stanley upped their price target on Belite Bio from $191.00 to $201.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Benchmark reissued a “buy” rating on shares of Belite Bio in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Belite Bio currently has an average rating of “Moderate Buy” and an average price target of $202.33.

Belite Bio Stock Performance

Shares of NASDAQ:BLTE opened at $173.30 on Friday. The company has a market capitalization of $6.50 billion, a P/E ratio of -75.35 and a beta of -1.46. The company’s 50-day moving average is $170.11 and its 200 day moving average is $124.77. Belite Bio has a fifty-two week low of $49.00 and a fifty-two week high of $200.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Darwin Global Management Ltd. bought a new stake in shares of Belite Bio during the fourth quarter valued at about $486,915,000. RA Capital Management L.P. purchased a new position in Belite Bio during the third quarter valued at approximately $64,750,000. RTW Investments LP boosted its holdings in Belite Bio by 128.9% in the 4th quarter. RTW Investments LP now owns 715,332 shares of the company’s stock valued at $114,425,000 after purchasing an additional 402,832 shares during the period. Millennium Management LLC grew its position in shares of Belite Bio by 2,594.6% during the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after purchasing an additional 538,141 shares in the last quarter. Finally, Perceptive Advisors LLC increased its holdings in shares of Belite Bio by 732.0% in the fourth quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock worth $66,262,000 after purchasing an additional 364,451 shares during the period. Institutional investors own 0.53% of the company’s stock.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short‑interest figures appear to show zero shares and a 0.0 days‑to‑cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short‑interest data neutral for near‑term price direction.
• Negative Sentiment: HC Wainwright reduced its near‑term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full‑year earnings increase uncertainty around near‑term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.